vx-745 has been researched along with pyrimidinones in 2 studies
| Studies (vx-745) | Trials (vx-745) | Recent Studies (post-2010) (vx-745) | Studies (pyrimidinones) | Trials (pyrimidinones) | Recent Studies (post-2010) (pyrimidinones) |
|---|---|---|---|---|---|
| 58 | 1 | 35 | 6,059 | 604 | 2,692 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doherty, JB; Natarajan, SR | 1 |
| Natarajan, SR; O'Keefe, SJ; O'Neill, EA; Thompson, JE; Wisnoski, DD | 1 |
1 review(s) available for vx-745 and pyrimidinones
| Article | Year |
|---|---|
P38 MAP kinase inhibitors: evolution of imidazole-based and pyrido-pyrimidin-2-one lead classes.
Topics: Binding Sites; Drug Design; Enzyme Inhibitors; Imidazoles; p38 Mitogen-Activated Protein Kinases; Pyridazines; Pyrimidines; Pyrimidinones; Structure-Activity Relationship | 2005 |
1 other study(ies) available for vx-745 and pyrimidinones
| Article | Year |
|---|---|
p38 MAP kinase inhibitors. Part 3: SAR on 3,4-dihydropyrimido[4,5-d]pyrimidin-2-ones and 3,4-dihydropyrido[4,3-d]pyrimidin-2-ones.
Topics: Chemistry, Pharmaceutical; Drug Design; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Models, Chemical; p38 Mitogen-Activated Protein Kinases; Pyridazines; Pyridines; Pyrimidines; Pyrimidinones; Quinazolines; Structure-Activity Relationship | 2006 |